Cantor Fitzgerald on TG Therapeutics (TGTX): 'Stock is at a very attractive valuation right now'

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).

The analyst comments "TG pre-announced 4Q and gave 2026 guide. 2026 Briumvi guide of $825-$850M is in-line with consensus at the top end but better than what many investors had feared based on some of the claims data trends in 4Q. TG always guides v. conservatively, and there is a path to do $870-$900M even if 2026 new patient starts are flat y/y or just grow modestly. SubQ Briumvi pivotal trial readout is within the next ~12 months, which we think is a very material catalyst for TG. Stock is at a very attractive valuation right now - our DCF value with conservative assumptions for subQ Briumvi is low $40s/sh (>50% upside), so we are surprised the stock hasn't traded up a lot more. BUY TGTX."

For an analyst ratings summary and ratings history on TG Therapeutics click here. For more ratings news on TG Therapeutics click here.

Shares of TG Therapeutics closed at $27.87 yesterday.

You May Also Be Interested In

• SpaceX (SPCX) gains nearly 6% as traders follow the money
• Synchrony partners with OpenAI to integrate AI into shopping
• argenx SE (ARGX) PT Raised to $1,150 at Wedbush